Piper Sandler Reiterates Overweight on Pelthos Therapeutics, Lowers Price Target to $21

Benzinga · 19h ago
Piper Sandler analyst David Amsellem reiterates Pelthos Therapeutics (AMEX:PTHS) with a Overweight and lowers the price target from $48 to $21.